StockNews.com initiated coverage on shares of Calithera Biosciences (NASDAQ:CALA – Get Rating) in a report released on Friday morning. The brokerage issued a hold rating on the biotechnology company's stock.

Calithera Biosciences Stock Down 50.0 %

NASDAQ:CALA opened at $0.02 on Friday. Calithera Biosciences has a 12-month low of $0.01 and a 12-month high of $5.39. The firm has a market capitalization of $97,400.00, a price-to-earnings ratio of 0.00 and a beta of 1.19. The stock's 50 day moving average price is $0.05 and its two-hundred day moving average price is $1.13.

Institutional Trading of Calithera Biosciences

Large investors have recently modified their holdings of the stock. Renaissance Technologies LLC raised its holdings in Calithera Biosciences by 36.5% in the 1st quarter. Renaissance Technologies LLC now owns 1,853,500 shares of the biotechnology company's stock valued at $749,000 after buying an additional 496,100 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Calithera Biosciences by 23.4% in the 3rd quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company's stock worth $415,000 after acquiring an additional 26,800 shares in the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of Calithera Biosciences during the 1st quarter worth $404,000. Affinity Asset Advisors LLC purchased a new stake in shares of Calithera Biosciences during the 1st quarter worth approximately $404,000. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Calithera Biosciences by 143.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company's stock valued at $50,000 after buying an additional 72,865 shares in the last quarter. 33.73% of the stock is owned by institutional investors and hedge funds.

Calithera Biosciences Company Profile

(Get Rating)

Calithera Biosciences, Inc is a clinical stage precision oncology biopharmaceutical company, which engages in developing targeted therapies to redefine treatment for biomarker-specific patient populations. It also focuses on researching small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic.

Featured Stories

• Get a free copy of the StockNews.com research report on Calithera Biosciences (CALA)
• MarketBeat Week in Review – 4/24 – 4/28
• How to Invest in the Top Grocery Stocks for This Year
• Array Technologies Brings Solar Flare To 2023 Earnings Forecast
• Best Bank Stocks to Invest in Ahead of Rising Interest Rates
• How to Invest in Farmland: 7 Simple Ways

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.